TIDMEVG

RNS Number : 5162S

Evgen Pharma PLC

14 July 2022

Evgen Pharma plc

("Evgen" or the "Company)

Investor presentation

14 July 2022, Alderley, Cheshire - Evgen Pharma plc announces that Dr Huw Jones, CEO and Richard Moulson, CFO will provide a live post-AGM presentation via the Investor Meet Company platform on 21 July 2022 at 3:30pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company free of charge and add to meet Evgen via this link: https://www.investormeetcompany.com/evgen-pharma-plc/register-investor

Investors who already follow Evgen on the Investor Meet Company platform will automatically be invited.

Enquiries:

 
 Evgen Pharma plc                        Tel: +44 1625 466591 
 Dr Huw Jones, CEO 
 Richard Moulson, CFO 
 
 FinnCap (Nominated Advisor and         Tel: +44 20 7220 0500 
  Broker) 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane/Nigel Birks (ECM) 
 
 Instinctif Partners                    Tel: +44 207 457 2020 
 Melanie Toyne-Sewell / Rozi Morris      Evgen@Instinctif.com 
 Agnes Stephens / Adam Loudon

Notes to Editors

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. It will be entering the clinic in glioma/glioblastoma later in 2022. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex(R) technology.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFZGMNMDLGZZM

(END) Dow Jones Newswires

July 14, 2022 07:43 ET (11:43 GMT)

Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Evgen Pharma.
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Evgen Pharma.